Project Grant R21AG085394
Award Date
9/30/24
Completion Date
8/31/26
Dollars Obligated
$446K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Piscataway, NJ 08854, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $795,436 to Rutgers, The State University of New Jersey to elucidate the role of the glycoproteome in Alzheimer's disease and related disorders (AD/ADRD). The award period is from Apr 1, 2025 to Feb 28, 2030. The study aims to: 1) identify glycopeptiforms related to AD/ADRD pathologies and clinical traits; 2) test if glycopeptiforms link an active lifestyle with brain health; and 3)...
This federal Project Grant award of $513,740.00 was provided by the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), to develop a novel exosome-based nano-scavenger (EBNS) for the targeted removal of amyloid-beta (Aβ) proteins associated with Alzheimer's disease (AD) and other amyloid-related disorders. The 3-year project aims to: 1) genetically engineer exosomes to load Aβ-targeting antibodies and Aβ-degrading enzymes; 2) establish isolation and...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant (CFDA 93.866 - Aging Research) to Florida International University to develop biotherapeutic nanogels for the treatment of Alzheimer's disease. The goal is to create a novel nanogel system that can effectively cross the blood-brain barrier, inhibit amyloid-beta aggregation, and reduce oxidative stress and neuroinflammation associated with Alzheimer's. The project will focus on improving the nanogel formulation for enhanced...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $636,000 to the University of Pittsburgh to investigate the use of NOX2 small molecule inhibitors as a potential therapeutic strategy for treating Alzheimer's disease (AD). The researchers aim to evaluate the ability of two novel, orally bioavailable, and blood-brain barrier penetrant NOX2 inhibitors (CPP11G and CPP11H) to improve cerebrovascular blood flow, reduce amyloid-beta deposition, and...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), aims to develop novel lipid nanoparticle (LNP) formulations for delivering nucleic acid-based therapeutics to the brain for treating Alzheimer's disease (AD). The $835,417 award will support research to synthesize BBB-crossing lipids, formulate LNP-RNA constructs, elucidate their trafficking across the blood-brain barrier, engineer siRNA and mRNA sequences to modulate APOE...
This federal Project Grant award R21NS135390 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders CFDA program (93.853), provides $444,555.00 to Cornell University for a research project titled "Reduced Alzheimer's Disease Progression and Neutrophil Adhesion via Competition Using Neutrophil-Derived or Engineered Nanoparticles." The project aims to develop a novel therapeutic...
This Project Grant award, totaling $679,424, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to Colorado State University. The project aims to test the efficacy of a novel therapeutic targeting neuroinflammation for protecting against brain aging and Alzheimer's disease-related pathology. Specifically, the research will evaluate the role of the neuroinflammation mediators NF-kB and NLRP3 using a novel class of small molecule...
This $6,226,692 project grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support research to examine the role of neuronal hyperexcitability and proteostasis (protein homeostasis) in the development of Alzheimer's disease (AD). The primary focus is on investigating how modifications in brain activity, particularly in the locus coeruleus (LC) and hippocampus (HPC) regions, can lead to the key pathological hallmarks of AD....
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $784,596 to Northeastern University to conduct comprehensive and cell type-specific proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The project aims to substantially expand understanding of protein dysfunctions in AD by applying state-of-the-art proteomic methods paired with proteogenomics across multiple brain regions, AD stages,...